News >

Pembrolizumab Plus Enzalutamide Shows Moderate Activity in mCRPC

Caroline Seymour
Published: Tuesday, Mar 17, 2020

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute

Julie N. Graff, MD

The addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) showed moderate but durable activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed on enzalutamide, according to findings from cohorts 4 and 5 of the phase II KEYNOTE-199 trial, said lead study author Julie N. Graff, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication